Jonathan D Schwarts, MD following an academic career marked by excellence in teaching, translational research and patient care, Dr Schwartz has demonstrated expertise in biopharmaceutical development. Specific strengths include comprehensive integration of scientific, clinical, operational, and regulatory issues, efficient translation of concepts into well-designed clinical programs, expert leadership of cross-functional teams, and mentorship of junior colleagues. Dr Schwartz oversaw the development of ramucirumab (CYRAMZA) from late Phase 1 into a multifaceted global Phase 3 program culminating in FDA, EMA and PMDA approval in stomach, liver, colorectal and non-small cell lung cancers. As a foundational executive officer of Rocket Pharma, Dr Schwartz was a core member of a leadership team that enabled growth from Series A start-up to a publicly traded, multiplatform gene therapy company (valuation >$2B) over 5 years, with 5 successful IND filings in 2018–20.
